Evaluation of Additive Neuroprotective Effect of Combination Therapy for Parkinson's Disease Using In Vitro Models.

Antioxidants (Basel) · 2025 · PMC12024093 · PMID 40298667

Europe PMC DOI

hedged sentence

0.1600

closest p · 3.2× alpha

0.1600

boldest claim

The sentences

a positive trendp = 0.16not close (p > 0.1)

While none of the other possible combinations of PBA, TUDCA and exendin showed any statistically significant changes over the untreated cells of this line, the triple combination PBA/TUDCA/EXD showed a positive trend with p = 0.16 ( Figure 4 ). 3.3.

also in 6,774 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.